DUBLIN--(BUSINESS WIRE)--The "Uterine Cancer Pipeline Highlights - 2017 Update" drug pipelines has been added to Research and Markets' offering.
Uterine cancer Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Uterine cancer market. It covers emerging therapies for Uterine cancer in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Uterine cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Uterine cancer pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
The report provides Uterine cancer pipeline products by the company.
Short-term Launch Highlights:
Find out which Uterine cancer pipeline products will be launched in the US and Ex-US till 2020.
Key Topics Covered:
1. Uterine cancer Pipeline by Stages
2. Uterine cancer Pipeline by Drug Class
3. Uterine cancer Pipeline by Company
4. Uterine cancer Phase 3 Clinical Trial Insights
5. Uterine cancer Phase 2 Clinical Trial Insights
6. Uterine cancer Phase 1 Clinical Trial Insights
7. Uterine cancer Preclinical Research Insights
8. Uterine cancer Discovery Stage Insights
9. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5tzzb9/uterine_cancer
